rTMS ameliorates the fear of cancer recurrence: a mechanism study protocol for the prefrontal amygdaloid-hippocampus pathway

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300070665

Enrollment

Unknown

Registered

2023-04-19

Start date

2023-07-01

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

rTMS group:rTMS group

sham group:sham group

Eligibility

Sex/Gender

Female

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: a) Adult; b) Breast cancer patients undergoing treatment for the first time; c) Able to understand and sign informed consent; d) Being able to comply with the intervention

Exclusion criteria

Exclusion criteria: a) Minors; b) Having a diagnosis of a significant untreated mental or medical illness (eg, consciousness disturbances, mania, acute phase of schizophrenia, major depressive disorder, etc.); c) Patients with recurrent cancer; d) Hospice patients.

Design outcomes

Secondary

Measure	Time frame
PHQ9;GAD7;Pittsburgh Sleep Quality Index, PSQI;	—

Primary

Measure	Time frame
fMRI;FCRQ7;	—

Countries

China

Contacts

Public ContactYang Yuan

Guangdong Provincial People's Hospital

yangyuan@gdph.org.cn+86 18825059293

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026